Phreesia, Inc. (NYSE: PHR), a leading healthcare technology company, saw its stock soar 5.13% in pre-market trading on Tuesday. This surge can be attributed to the company's impressive third-quarter fiscal 2025 results and an optimistic outlook for the upcoming fiscal year.
In its earnings report, Phreesia announced a 17% year-over-year increase in revenue, reaching $106.8 million. The company also reported positive adjusted EBITDA of $9.8 million, a significant improvement of $16.4 million compared to the previous year. Additionally, Phreesia achieved positive operating cash flow of $5.8 million and free cash flow of $1.6 million, further strengthening its financial position.
Encouraged by the strong performance, Phreesia raised its fiscal 2025 adjusted EBITDA guidance to a range of $34 million to $36 million, up from the previous range of $26 million to $31 million. Furthermore, the company provided an optimistic outlook for fiscal 2026, expecting revenue to grow by 13% to 15% and adjusted EBITDA to increase by a staggering 129% to 144%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。